Breast Cancer (update of QLQ-BR23)

Gender Neutral
Type Module
Testing Phase IV - pending
Principal investigator(s)
Vesna Bjelic-Radisic
Medical University Graz, Department of Obstetrics and Gynecology
Graz, Austria
Study coordinator(s)
Brigitte Bliem
Medical University of Graz
Graz, Austria

Project summary

The standard therapy of breast cancer has been changed, new therapies brought new side effects and different impacts on quality of life are not sufficiently covered by EORTC QLQ BR-23.

 

Achievements

Phases 1 and 2 are completed, the Breast Cancer Module Update has been translated into 11 languages, patient recruitment for phase 3 is finished and data has been evaluated. The manuscript is in progress.

Future plans

Phase 4 field study will be started in spring 2019.

Patient recruitment and data collection for phase 4.

For patients

BR-23 is the standard instrument for measuring the quality of life (QoL) in patients with breast cancer. It was developed in 1996. But since this time, changes in treatment have occurred, making an update of the questionnaire necessary. We updated QLQ BR 23. The new QLQ BR 45   contains 45 items. Now we will start with the phase IV  of the study, a large scale field study.